Thrombotic Complications in Immune Thrombocytopenia Patients Treated with Avatrombopag

Avatrombopag is a novel oral non-peptide thrombopoietin receptor agonist (TPO-RA) that was approved by the FDA as a second-line therapy for chronic immune thrombocytopenia (cITP). Avatrombopag has shown promising results in regards to efficacy and tolerability, but to our knowledge, there are no rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelsamia, Mahmoud, Farid, Saira, Dean, Steven, Cataland, Spero R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531320/
https://www.ncbi.nlm.nih.gov/pubmed/37754669
http://dx.doi.org/10.3390/hematolrep15030054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531320/
https://www.ncbi.nlm.nih.gov/pubmed/37754669
http://dx.doi.org/10.3390/hematolrep15030054

Ejemplares similares